The Trump administration has granted federal recognition to medical cannabis dispensaries for the first time, ending a decades‑long legal clash. The Justice Department confirmed Friday that more than 900 dispensaries in seven states have received DEA registration.
Federal DEA Registers Dispensaries
The registrations cover Alabama, Florida, Mississippi, South Dakota, Texas, Virginia and West Virginia. Each business must prove a state license, meet security standards and maintain inventory controls.
Nearly 7,000 medical cannabis firms nationwide have filed applications, including over 4,000 dispensaries, manufacturers and distributors. The DEA will review the remaining requests in phases.
The move implements the reform President Donald Trump promoted in April, when the Justice Department ordered medical cannabis reclassified from Schedule I to Schedule III. Schedule III acknowledges accepted medical use while retaining federal controls.
Attorney General Todd Blanche said, “The American people deserve access to the best medical treatments in the world.” He added that federally registered dispensaries will expand chronic pain treatment and protect public safety, but the department will still prosecute illegal trafficking.
The registration opens the door to major tax relief. Cannabis businesses have been barred from deducting salaries, rent or advertising because of Schedule I status, but DEA registration will allow standard business deductions.
The announcements came days before the 30th anniversary of California’s 1996 medical cannabis legalization, the first state to approve the drug. Today, medical cannabis programs operate in 40 states.
Steph Sherer, founder of Americans for Safe Access, called the federal registrations a major victory for patients, noting that the government finally recognizes the dispensaries patients fought to establish for three decades. She said the recognition validates decades of advocacy.
Federal registration does not equate to FDA medical approval; the agency has not approved the cannabis plant itself, though it has authorized cannabis‑derived drugs. The decision also leaves recreational use illegal at the federal level.
The paradox persists: New York allows adult‑use purchase without medical justification, while Texas restricts patients to strict treatment criteria. State law, not federal policy, ultimately determines who can use cannabis.
